Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

In Vitro Diagnostics Market Report Unveils Key Commercial Prospects

globenewswire.com
GH Utilizes circulating tumor DNA for detecting cancer recurrences sooner than traditional imaging, paving the way for timely interventions and personalized treatment strategies in oncology diagnostics. NTRA Utilizes circulating tumor DNA for detecting cancer recurrences sooner than traditional imaging, paving the way for timely interventions and personalized treatment strategies in oncology diagnostics. EXAS Utilizes circulating tumor DNA for detecting cancer recurrences sooner than traditional imaging, paving the way for timely interventions and personalized treatment strategies in oncology diagnostics. QGEN Profiled as a leading company in the IVD industry with market strategies and growth prospects detailed in the report. BDX Profiled as a leading company in the IVD industry with market strategies and growth prospects detailed in the report.

Dublin, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The "In Vitro Diagnostics Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.

The global In Vitro Diagnostics (IVD) market is poised for robust growth, expected to surpass US$95 billion by 2025, according to a new comprehensive market report. The prediction spans a decade ahead to 2035, offering valuable insights into which organizations have the most significant potential by examining their capabilities, progress, and commercial prospects. The expansion in the IVD sector is being fueled by technological advancements that enhance the precision, portability, and affordability of diagnostic technologies.

In a landmark advancement, the FDA approved the first blood test for diagnosing Alzheimer's disease in May 2025, marking a significant step for early detection and management, especially beneficial to the aging population. Concurrently, the adoption of blood-based tests for detecting minimal residual disease (MRD) is transforming oncology diagnostics. Key players like Guardant Health, Natera, and Exact Sciences utilize circulating tumor DNA for detecting cancer recurrences sooner than traditional imaging methods. These advancements pave the way for timely interventions and personalized treatment strategies.

As of 2025, the reagents segment stands strong, comprising over 60% of the IVD market share. It remains the fastest-growing segment, expected to lead through continuous innovation and development of novel diagnostic reagents and kits. A case in point is Werfen's Aptiva reagents, recently cleared by the FDA for enhanced autoimmune diagnostics, offering improved specificity and efficiency. The surge in demand for personalized medicine further drives the growth of companion diagnostics, integral to precision medicine by offering comprehensive insights into genetic alterations for tailored cancer treatments.

The report also explores the impact of U.S. trade tariffs on the global IVD market. These tariffs could significantly alter cost structures and supply chain dynamics. Affected goods include imported IVD products like reagents and analyzers, potentially elevating costs for U.S. firms and healthcare providers. This scenario may lead to realignment in sourcing or manufacturing, increasing complexity and expenses, while in some regions, it might foster local production and regional alliances, reshaping global competitive dynamics.

Key questions addressed in the report include the market's evolution, drivers and restraints, submarket growth, and competitive dynamics from 2025 to 2035. The extensive 356-page report, featuring 125 tables and 212 charts/graphs, provides in-depth analysis at global, regional, and national levels. Highlights include successful trends, revenue projections, and insights into lucrative areas of the industry for targeted strategies.

Further, the report provides comprehensive revenue forecasts and analysis categorized by product type, test category, application area, and end-user profile. It covers five major regions-North America, Europe, Asia-Pacific, Latin America, and MEA-and 20 leading national markets. Profiles of leading companies, such as QIAGEN, BD, and Roche, are included, detailing their market strategies and growth prospects in the IVD industry.

Offering a blend of qualitative and quantitative analyses, the report includes independent predictions, market dynamics, and strategic insights into the IVD industry, making it an essential tool for market participants seeking to capitalize on emerging opportunities.

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/k7fs14

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.